藥物成癮是一種慢性復(fù)發(fā)性腦疾病，導(dǎo)致嚴(yán)重的醫(yī)學(xué)、精神和社會經(jīng)濟(jì)問題。目前已獲批上市抗成癮藥物以納曲酮、美沙酮、丁丙諾啡為主。研發(fā)自身不成癮且有效對抗復(fù)吸的、不良反應(yīng)低的廣譜性抗成癮藥物對于成癮的防治具有重要意義。大麻二酚具有良好的抗成癮、防復(fù)吸的藥效學(xué)作用，可抗阿片類藥物成癮、抗可卡因和合成苯丙胺類物質(zhì)成癮、抗酒精成癮、抗尼古丁成癮、抗新型精神活性物質(zhì)成癮?？偨Y(jié)了大麻二酚抗藥物成癮的臨床前、臨床研究進(jìn)展，為多角度認(rèn)識大麻二酚作為治療藥物成癮的候選藥物的潛力提供參考。

Drug addiction is a chronic recurrent brain disease that leads to serious medical, mental, and socio-economic problems. At present, the approved anti addiction drugs on the market are mainly naltrexone, methadone, and buprenorphine. Anti addiction drugs that are not addictive themselves and effectively in combating relapse with low adverse reactions are of great significance for the prevention and treatment of addiction. Cannabidiol has good pharmacological effects on anti addiction and anti relapse. Cannabidiol can resist addiction to opioid drugs, cocaine and synthetic amphetamine substances, alcohol, nicotine, and new psychoactive substances. This article summarizes the preclinical and clinical research progress of cannabidiol in treatment of drug addiction, providing reference for the potential of cannabidiol as a candidate drug for treating drug addiction from multiple perspectives.

R971

國家重點研發(fā)計劃（2023YFC3304201）